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Abstract
Mesenchymal stem cells (MSCs) are multipotent cells which reside in many tissues and can give rise to multiple lineages
including bone, cartilage and adipose. Although MSCs have attracted significant attention for basic and translational
research, primary MSCs have limited life span in culture which hampers MSCs’ broader applications. Here, we investigate if
mouse mesenchymal progenitors can be conditionally immortalized with SV40 large T antigen and maintain long-term
cell proliferation without compromising their multipotency. Using the system which expresses SV40 large T antigen
flanked with Cre/loxP sites, we demonstrate that mouse embryonic fibroblasts (MEFs) can be efficiently immortalized by
SV40 large T antigen. The conditionally immortalized MEFs (iMEFs) exhibit an enhanced proliferative activity and maintain
long-term cell proliferation, which can be reversed by Cre recombinase. The iMEFs express most MSC markers and retain
multipotency as they can differentiate into osteogenic, chondrogenic and adipogenic lineages under appropriate
differentiation conditions in vitro and in vivo. The removal of SV40 large T reduces the differentiation potential of iMEFs
possibly due to the decreased progenitor expansion. Furthermore, the iMEFs are apparently not tumorigenic when they
are subcutaneously injected into athymic nude mice. Thus, the conditionally immortalized iMEFs not only maintain long-
term cell proliferation but also retain the ability to differentiate into multiple lineages. Our results suggest that the
reversible immortalization strategy using SV40 large T antigen may be an efficient and safe approach to establishing long-
term cell culture of primary mesenchymal progenitors for basic and translational research, as well as for potential clinical
applications.
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Introduction
Mesenchymal stem cells (MSCs) are non-hematopoietic mul-
tipotent cells, which have the capacity to differentiate into tissues
of both mesenchymal and non-mesenchymal origin [1–6]. MSCs
can differentiate into osteoblastic, chondrogenic, and adipogenic
lineages [1–6], although it has recently been reported that MSCs
are also able to differentiate into other lineages, including neuronal
[7–9] and cardiomyogenic [10] lineages. Unlike hematopoietic or
neuronal stem cells, MSCs usually lack specific markers.
Nonetheless, it is generally accepted that MSCs have to satisfy
three criteria [11]. First, MSCs must be plastic-adherent when
maintained in standard culture conditions using tissue culture
flasks. Second, more than 95% of the MSC population must
express CD105, CD73 and CD90, but must lack expression (,2%
positive) of CD45 and CD34. Third, the cells must be able to
differentiate to osteoblasts, adipocytes and chondroblasts under
standard in vitro differentiating conditions [11].
MSCs have attracted significant attention for their potential
role in elucidating stem differentiation pathways, promoting
tissue engineering for regenerative medicine, and functioning as
gene vectors and immunomodulators in autoimmune diseases
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32428[5,6,12–16]. In addition to bone marrow, MSCs have been
isolated from almost every type of tissue, including periosteum,
brain, liver, bone marrow, adipose, skeletal muscle, amniotic fluid
and hair follicle [17–26]. While MSCs isolated from various
tissues share many similar characteristics, they exhibit minor
differences in their expression profile and differentiation potential
[27].
One of the major technical challenges is to isolate sufficient
MSCs for in vitro and in vivo studies, as well as to expand MSCs for
possible clinical applications. For example, in bone marrow MSCs
only make up a minute fraction of nucleated cells and account for
approximately 0.001%–0.01% of all cells in each aspirate,
depending on the technique [2]. The therapeutic application of
MSCs would need an even large number of cells, which requires ex
vivo expansion post-harvest [5,6,12].
In this study, we sought to investigate if conditionally
immortalized mesenchymal progenitor cells can maintain long-
term cell proliferation without compromising the multipotent
differentiation potential. Technologically, we take advantage of
the previously characterized reversible immortalization system,
which expresses SV40 T antigen flanked with Cre/loxP sites [28].
We have demonstrated that mouse embryonic fibroblasts (MEFs)
can be effectively immortalized with an enhanced proliferative
activity. The immortalized MEFs (iMEFs) express most of the
MSC markers (CD90/Thy-1
+, CD73
+, CD105/Endoglin
+,
CD166/ALCAM
+,a n dC D 4 4
+), suggesting that the iMEFs
may be MSC-like. We previously demonstrated that BMP9
(aka, growth and differentiation factor 2, or GDF2) is one of the
most potent factors that can induce osteogenic and adipogenic, to
a lesser extent, chondrogenic differentiation [29–33]. We
demonstrate that BMP9 can up-regulate the key lineage-specific
regulators Runx2 (osteogenic), Sox9 (chondrogenic) and PPARc2
(adipogenic), and that BMP9 can induce osteogenic marker
alkaline phosphatase activity (ALP) and matrix mineralization in
the iMEFs in vitro. Moreover, the iMEFs are able to undergo
terminal adipogenic differentiation upon BMP9 or PPARc2
stimulation. Introduction of Cre recombinase into the iMEFs
effectively removes SV40 large T antigen and results in a
significant decrease in cell proliferation. Furthermore, in vivo stem
cell implantation studies indicate that the iMEFs are able to bone,
cartilage and adipose tissues upon BMP9 stimulation, whereas in
the presence of Cre recombinase the ability of iMEFs to
differentiate into these tissues is decreased possibly due to the
reduced expansion of progenitor population. Lastly, we demon-
strate that the iMEFs fail to form any subcutaneous tumors when
injected into athymic nude mice for up to 10 weeks. Taken
together, our results have demonstrated that the conditionally
immortalized iMEFs not only maintain long-term cell prolifera-
tion but also retain the ability to differentiate into multiple
lineages. The reversible SV40 T-mediated immortalization
strategy should be used to establish stable cells from primary
progenitors isolated from limited tissue sources, which may be
critical for basic and translational studies.
Materials and Methods
Cell culture and chemicals
Human bone marrow stromal stem cells were purchased from
ScienCell Research Laboratories (Carlsbad, CA). Human osteo-
sarcoma line 143B and HEK-293 cells were from ATCC
(Manassas, VA). The cells were maintained in the completed
DMEM medium described [29,34–37]. Unless indicated other-
wise, all chemicals were purchased from Sigma-Aldrich or Fisher
Scientific.
Isolation of mouse embryo fibroblasts (MEFs) and
establishment of reversibly immortalized MEFs (iMEFs)
MEFs were isolated from post coitus day 12.5–13.5 CD1 mice
as previously described [37–39]. Each embryo was dissected into
10 ml sterile PBS, voided of its internal organs, and sheared
through an 18-gauge syringe in the presence of 1 ml 0.25% trypsin
and 1 mM EDTA. After 15 min incubation with gentle shaking at
37uC, DMEM with 10% fetal bovine serum (FBS) was added to
inactivate trypsin. The cells were plated on 100 mm dishes and
incubated for 24 h at 37uC. Adherent cells were used as MEF
cells. Aliquots were kept in a liquid nitrogen tank. All MEFs used
in this study were within five passages.
To establish the immortalized MEFs (iMEFs), early passage
MEFs (,3 passages) were seeded in 25 cm
2 flasks and infected
with packaged retrovirus SSR #69, which expresses SV40 T Ag
flanked with Cre/loxP sites (Fig. 1A) [28]. Stable iMEF cell pools
were established by selecting the infected cells with hygromycin B
(at 4 mg/ml) for one week. Aliquots of the iMEFs were kept in
liquid nitrogen tanks. Human bone marrow stromal stem cells
were immortalized in a similar fashion.
Recombinant adenoviruses expressing BMP9, PPARc2,
Cre and GFP
Recombinant adenoviruses were generated using the AdEasy
technology as described [29,30,32,40–42]. The coding regions of
human BMP9, mouse PPARc2, Cre recombinase and green
fluorescence protein (GFP) were PCR amplified and cloned into
an adenoviral shuttle vector and subsequently used to generate
recombinant adenoviruses in HEK293 cells. The resulting
adenoviruses were designated as AdBMP9, AdPPARc2 and Ad-
Cre, which also express GFP as a marker for monitoring infection
efficiency. Analogous adenovirus expressing only GFP (AdGFP)
was used as controls [37,38,40–47].
RNA isolation and semi-quantitative RT-PCR analysis
Total RNA was isolated using TRIZOL Reagents (Invitrogen).
Total RNA was used to generate cDNA templates by RT reaction
with hexamer and M-MuLV Reverse Transcriptase (New England
Biolabs, Ipswich, MA). The first strand cDNA products were
further diluted 5- to 10-fold and used as PCR templates. Semi-
quantitative RT-PCR was carried out as described [32,34,37,
38,47–50]. PCR primers for mouse Runx2 (59-CCG GTC TCC
TTC CAG GAT-39 and 59-GGG AAC TGC TGT GGC TTC-
39), Sox9 59-AGC TCA CCA GAC CCT GAG AA-39 and 59-
TCC CAG CAA TCG TTA CCT TC-39), PPARc25 9-ACT
GCC GGA TCC ACA AAA-39 and 59-TCT CCT TCT CGG
CCT GTG-39) transcripts were designed by using Primer3 Plus
program (http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi) to amplify the genes of interest (approximately
150–180 bp). A touchdown cycling program was as follows: 94uC
for 2 min for 1 cycle; 92uC for 20 s, 68uC for 30 s, and 72uC for
12 cycles with a decrease in 1uC per cycle; and then at 92uC for
20 s, 57uC for 30 s, and 72uC for 20 s for 20–25 cycles, depending
on the abundance of a given gene. The specificity of PCR products
were confirmed by resolving PCR products on 1.5% agarose gels.
All samples were normalized by the expression level of GAPDH.
Alkaline phosphatase (ALP) activity assay
ALP activity was assessed quantitatively with a modified assay
using the Great Escape SEAP Chemiluminescence assay kit (BD
Clontech, Mountain View, CA) and qualitatively with histochem-
ical staining assay (using a mixture of 0.1 mg/ml napthol AS-MX
phosphate and 0.6 mg/ml Fast Blue BB salt) as described
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in triplicate and the results were repeated in at least three
independent experiments. ALP activity was normalized by total
cellular protein concentrations among the samples.
Matrix mineralization assay (Alizarin Red S staining)
MEFs were seeded in 24-well cell culture plates and infected
with AdBMP9 or AdGFP. Infected cells were cultured in the
presence of ascorbic acid (50 mg/mL) and b-glycerophosphate
(10 mM). At 14 days after infection, mineralized matrix nodules
were stained for calcium precipitation by means of Alizarin Red S
staining as described [29,30,32,34,37–39,45–47]. Cells were fixed
with 0.05% (v/v) glutaraldehyde at room temperature for 10 min
and washed with distilled water, fixed cells were incubated with
0.4% Alizarin Red S (Sigma-Aldrich, St. Louis, MO) for 5 min,
followed by extensive washing with distilled water. The staining of
calcium mineral deposits was recorded under bright field
microscopy.
Immunofluorescence staining
Immunofluorescence staining was performed as described
[32,34,37,48–50]. Briefly, cells were fixed with methanol,
permeabilized with 1% NP-40, and blocked with 10% BSA,
followed by incubating with CD73, CD44, CD90, CD117/c-kit,
CD29, CD133, CD105/endoglin, CD166/ALCAM, or BMPR-II
antibody (Santa Cruz Biotechnology) for 1 h. After washing, cells
were incubated with Texas Red-labeled secondary antibody
(Santa Cruz Biotechnology) for 30 min. Cell nuclei were stained
with DAPI. Stains were examined under a fluorescence micro-
scope. Stains without primary antibodies, or with control IgG,
were used as negative controls.
Immunohistochemical staining
Cultured cells were infected with adenoviruses. At the indicated
time points, cells were fixed with 10% formalin and washed with
PBS. The fixed cells were permeabilized with 1% NP-40 and
blocked with 10% goat serum, followed by incubation with an
anti-osteocalcin, or osteopontin antibody (Santa Cruz Biotechnol-
ogy) for 1 h. After washing, cells were incubated with biotin-
labeled secondary antibody for 30 min, followed by incubating
cells with streptavidin-HRP conjugate for 20 min at room
temperature. The presence of the expected protein was visualized
by DAB staining and examined under a microscope. Stains
without the primary antibody, or with control IgG, were used as
negative controls.
Western blotting analysis
Western blotting was performed as previously described
[37,39,47–52]. Briefly, cells were collected in Lysis Buffer. Cleared
total cell lysate was denatured by boiling and loaded onto a 10%
gradient SDS–PAGE. After electrophoretic separation, proteins
were transferred to an Immobilon-P membrane. Membrane was
blocked with SuperBlock Blocking Buffer, and probed with the
primary antibodies, anti-SV40 T Ag or anti-b-actin (Santa Cruz
Biotechnology, Santa Cruz, CA), followed by incubation with a
secondary antibody conjugated with horseradish peroxidase. The
proteins of interest were detected by using SuperSignal West Pico
Chemiluminescent Substrate kit.
Subcutaneous stem cell implantation
All animal work was conducted according to relevant national
and international guidelines. The animal welfare, use, and care
were carried out according to the approved Institutional Animal
Care and Use Committee (IACUC) of The University of Chicago
(protocol # 71108). Stem cell-mediated ectopic bone formation
was done as described [29,30,32,37–39]. Briefly, MEFs cells were
infected with AdBMP9 or AdRFP for 16 h, collected and
resuspended in PBS for subcutaneous injection (5610
6/injection)
into the flanks of athymic nude (nu/nu) mice (5 animals per group,
4–6 wk old, female, Harlan Sprague-Dawley). At 4 wk after
implantation, animals were sacrificed, and the implantation sites
were retrieved for histologic evaluation, and other specialty stains.
Xenogen bioluminescence imaging of iMEF
subcutaneous injection
The iMEFs were stably labeled with firefly luciferase and
injected into the flanks of anythmic nude mice (2610
6 cells/
injection; n=6, 4–6 wk old, female, Harlan Sprague-Dawley)
Figure 1. Morphology of primary and immortalized mouse
embryonic fibroblasts (MEFs). (A) Schematic representation of the
reversible immortalization vector SSR #69 [28]. This retroviral vector
contains the hygromycin and SV40 T antigen expression cassette
flanked by loxP sites. (B) Morphology of primary MEFs in cell culture.
Primary MEFs were seeded at 20–30% confluence and passed
consecutively for five passages (P5). (C) Morphology of the reversibly
immortalized MEFs (iMEFs) in cell culture. The iMEF cells were seeded at
low density and passed consecutively for 15 passages (P15).
doi:10.1371/journal.pone.0032428.g001
Immortalized MSCs Retain Multipotency
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32428[34,42,51,53]. At the indicated time points, animal were
anesthetized with isoflurane attached to a nosecone mask within
Xenogen IVIS 200 imaging system. For bioluminescence imaging,
animals were injected (i.p.) with D-Luciferin sodium salt (Gold
BioTechnology) at 100 mg/kg in 0.1 ml sterile saline. Pseudoi-
mages were obtained by superimposing the emitted light over the
gray-scale photographs of the animals.
Hematoxylin & eosin, trichrome, and alcian blue staining
Retrieved tissues were fixed in 10% formalin overnight and
embedded in paraffin. Serial sections of the embedded specimens
were stained with hematoxylin and eosin (H & E). Trichrome and
alcian blue stains were carried out as previously described
[29,30,32].
Results
Immortalized mouse embryonic fibroblasts (iMESs)
exhibit high proliferative activity
Numerous studies have been recently carried out to induce the
pluripotency of fibroblasts and MEFs through reprogramming
stem cell differentiation capability with a set of defined factors,
such as Oct3/4, Sox9, Klf4, and c-Myc [54–57]. We sought to
investigate whether immortalized MEFs retain the multipotent
properties of mesenchymal stem cells (MSCs) by taking advantage
of a previously characterized reversible immortalization system
using SV40 T antigen (Fig. 1A) [28]. The reversible immortal-
ization vector SSR #69 contains the hygromycin and SV40 T
antigen expression cassette flanked with loxP sites [28]. Primary
MEFs were shown to grow fairly well, albeit at lower rate, up to at
least five passages (Fig. 1B). The immortalized MEFs (iMEFs)
grew more rapidly and maintained a high proliferation rate after
15 passages (Fig. 1C). In fact, iMEFs have been passed more than
50 generations by now and proliferate well. Thus, these results
indicate that we successfully immortalized MEFs in vitro.
Next, we quantitatively compared the proliferative activity
between primary MEFs and iMEFs. Crystal violet staining assay
indicated that iMEF cells reached complete confluence at day 3
while MEF cells reached complete confluence at day 5 when both
started with a similar cell density (Fig. 2A). A quantitative
assessment of the stained cells confirmed the staining results and
revealed that iMEFs had significantly higher cell staining at each
given time points than that of the MEFs (Fig. 2B). The iMEF cells
exhibited a higher proliferation rate than that of MEFs in MTT
assay when the same number of primary MEF and iMEF cells was
seeded at a low density (Fig. 2C). Direct cell counting experiment
further confirmed that iMEF cells grow faster than MEFs
(Fig. 2D). Taken together, these results demonstrate that
immortalized MEFs can be maintained in culture and exhibit
much higher proliferation rate.
Figure 2. The iMEFs exhibit higher proliferative activity than that of primary MEFs. (A) and (B) Cell viability and proliferation assay by
crystal violet staining assay. The same number of primary MEF and iMEF cells was seeded at a low density. Cells were stained with crystal violet at the
indicated time points (A) and the viable and stained cells were dissolved for OD reading as previously described (B) [42]. (C) Cell proliferation assessed
with MTT assay. The same cell number of primary MEFs and iMEFs was seeded at a low density. Cells were collected for MTT assay at the indicated
time points. (D) Cell counting assay. The same number of primary MEF and iMEF cells was seeded at 20% confluence. Cells were trypsinized, stained
with Trypan blue, and counted at the indicated time points. For all of the above assays, each assay condition was done in triplicate. The assays were
repeated in at least two independent batches. Representative results are shown.
doi:10.1371/journal.pone.0032428.g002
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To assert if iMEFs possess MSC-like multipotency, we
characterized the expression of MSC markers using immunoflu-
orescence staining. It has been reported that the consensus human
MSC markers include CD90/Thy-1, CD73, CD105/Endoglin,
CD166/ALCAM and CD44 [11]. Although mouse MSCs do not
necessarily express all the same molecules as those on human cells,
we found that all of these markers were readily detectable in
iMEFs by immunofluorescence staining (Fig. 3). Flow cytometry
indicated that more than 90% of MSC population expresses these
markers (data not shown). Furthermore, we found that the
expression of CD45 and CD34 was not detectable (data not
shown). Thus, these results demonstrate that the iMEFs express
most if not all of the conventional MSC markers, suggesting that
these cells may possess MSC-like phenotypes.
iMEF cells are capable of differentiating into osteogenic,
chondrogenic, and adipogenic lineages
Given the fact that MSC markers are not specific and unique,
MSCs are by definition required to give rise to at least osteogenic,
chondrogenic and adipogenic lineages [1–5]. We tested if the
iMEFs were able to differentiate into these lineages. We have
demonstrated that BMP9 is one of the most potent factors that can
induce osteogenic and adipogenic, to a lesser extent, chondrogenic
differentiation [29–33]. When the iMEFs were transduced with
BMP9 or GFP adenoviral vector, the three key lineage-specific
regulators, Runx2 (osteogenic), Sox9 (chondrogenic) and PPARc2
(adipogenic), were significantly up-regulated at as early as day 3
(Fig. 4A). We further analyzed the early osteogenic marker
alkaline phosphatase (ALP) in these cells. As shown in Fig. 4B,
BMP9 induced much higher ALP activity at day 5 in the iMEFs
than that in primary MEFs. The ALP activity induced by BMP9 in
iMEFs and MEFs was also confirmed quantitatively (Fig. 4C).
The BMP9-transduced iMEFs were further shown to effectively
undergo late stage of osteogenic differentiation as evidenced by
matrix mineralization assessed with Alizarin Red S staining
(Fig. 4D).
We next analyzed the adipogenic potential of iMEFs. In
addition to BMP9, PPARc2 has been shown to induce adipogenic
differentiation of MSCs [32]. When the iMEFs were transduced
with PPARc2 adenoviral vector, a significant portion of the cells
underwent terminal adipogenic differentiation as evidenced by Oil
Red-O staining (Fig. 4E, panels a and b). Furthermore, when
iMEF cells were stimulated with BMP9 for 10 days, a double
staining of the transduced cells for ALP activity and Oil Red-O
positivity revealed that iMEFs stimulated by BMP9 can undergo
either osteogenic or adipogenic differentiation, a process was
shown to be mutually exclusive (Fig. 4E, panels c and d). These
results are consistent with what we previously reported in MSCs
[29–33]. Furthermore, using the same procedure, we immortal-
ized human bone marrow stromal stem cells and found that the
immortalized bone marrow stromal cells also acquired long-term
proliferative capability but retained the ability to undergo
osteogenic (Fig. 4F, panel a) and adipogenic potential (Fig. 4F,
panel b) upon BMP9 stimulation. Taking the in vitro results
together, we have demonstrated that the iMEFs are multipotent
and capable of differentiating into osteogenic, chondrogenic and
adipogenic lineages.
The enhanced proliferative activity of the iMEFs can be
reversed by Cre recombinase
We sought to text if the immortalization-related phenotypes of
the iMEFs could be reversed. As shown in Fig. 1A, the
immortalizing gene SV40 large T antigen could be removed
through the action of Cre recombinase on the flanking loxP sites.
To effectively express Cre in the iMEFs, we constructed a
recombinant adenoviral vector AdCre, which was shown to
transduce iMEFs with high efficiency (Fig. 5A, panels a & b). The
efficient removal of SV40 T antigen by Cre expression was shown
using anti-T antigen Western blotting in AdCre infected iMEFs,
but not in the GFP control (Fig. 5A, panel c). Cell proliferation
rate of the AdCre-transduced iMEFs was significantly decreased in
both cell counting (Fig. 5B) and Crystal violet staining (Fig. 5C)
assays. Thus, these results indicate that the proliferative activity of
the iMEFs can be effectively reversed by Cre recombinase.
We further analyzed the differentiation potential of the Cre-
transduced iMEFs. When iMEFs were infected with AdCre or
AdGFP in the presence of BMP9, the ALP activity was induced in
Cre-transduced iMEFs, albeit to a much lower extent than that of
the GFP controls (Fig. 5D). The effect of Cre-mediated reversal on
late stage differentiation of the iMEFs was also examined. When
subconfluent iMEFs were infected with AdCre or AdGFP for 14
Figure 3. The iMEFs express most mesenchymal stem cell markers. The iMEF cells were seeded at subconfluency for 24 h and stained with
MSC marker antibodies as indicated. The consensus MSC markers include CD44, CD90/Thy-1, CD73, CD105/Endoglin and CD166/ALCAM [11]. Cell
nuclei were stained with DAPI. Respective IgG Isotypes were used as immunostaining control.
doi:10.1371/journal.pone.0032428.g003
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a & b) and Oil Red-O staining (Fig. 5E panels c and d), or
immunostained against osteogenic late markers osteopontin
(Fig. 5E panels e and f) and osteocalcin (Fig. 5E panels g and h).
In these assays, Cre-tranduced iMEFs were still able to differentiate
into osteogenic and adipogenic lineages, which were significantly
less effective than the GFP controls. Thus, these results strongly
suggest that Cre-mediated reversal of the immortalization pheno-
types may significantly reduce the differentiation potential of iMEFs
due to the decrease in progenitor cell repopulation.
iMEFs can effectively induce ectopic bone formation,
chondrogenesis and adipogenesis upon BMP9
stimulation in vivo
We next tested if the iMEFs would be able to undergo multi-
lineage differentiation in vivo. Using the well-established stem cell
implantation assay [29,30,32,37–39], we co-transduced iMEFs
with AdBMP9 and AdCre or AdGFP in culture and injected the
cells subcutaneously into anthymic nude mice. Bony masses were
retrieved from mice after 4 weeks (Fig. 6A), while no masses were
formed in the cells transduced with AdGFP or AdCre alone (data
Figure 4. Induction of osteogenic, chondrogenic, and adipogenic lineage markers in iMEFs. (A) Expression of lineage-specific regulators
in iMEFs stimulated by BMP9. Subconfluent iMEF cells were infected with AdBMP9 or AdGFP. Total RNA was isolated at the indicated time points and
subjected to RT-PCR reactions. The cDNA products were used as templates for semi-quantitative amplification of mouse Runx2, Sox9 and PPARc2
transcripts. All samples were normalized with GAPDH expression levels. (B) and (C) Induction of early osteogenic marker alkaline phosphatase (ALP)
in primary MEFs and iMEFs. Subconfluent primary MEFs and iMEFs were infected with AdBMP9 or AdGFP. ALP activity was histochemically stained on
day 5 (B) or quantitatively determined at days 3, 5 and 7 (C). The ALP activity was normalized with total cellular protein (TCP) (C). (D) Matrix
mineralization assessed with Alizarin Red S staining. Subconfluent MEFs and iMEFs were infected with AdBMP9 or AdGFP for 14 days. Cells were fixed
and stained with Alizarin Red S. (E) Adipogenic differentiation assessed with Oil Red O staining. Subconfluent iMEFs were infected with AdBMP9,
AdPPARc2, or AdGFP for 10 days. Cells were fixed and stained with Oil Red O staining (panels a and b), or stained for ALP activity, followed by Oil-Red
O staining (panels c and d). (F) Osteogenic and adipogenic differentiation of immortalized human bone marrow stromal stem cells. Subconfluent cells
were infected with AdBMP9 or AdGFP. ALP staining was carried out at day 7 (a) while Oil-red O staining was done at day 14 (b). Each assay condition
was done in triplicate. The assays were repeated in at least two independent batches. Representative results are shown.
doi:10.1371/journal.pone.0032428.g004
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removal of SV40 T antigen from iMEFs led to form smaller
masses than that of GFP controls (Fig. 6A). H & E staining of the
retrieved masses indicate that Cre-transduced iMEFs seemingly
formed more mature and fully mineralized osteoid matrix
(Fig. 6B, panel a) than that of the GFP control group (Fig. 6B,
panel b). Nonetheless, adipocytes and chondrocytes were readily
detected (Fig. 6B). Masson trichrome staining confirmed that
both mineralized osteoid matrix and osteoid matrix were
presented in Cre-treated and GFP-treated samples (Fig. 6C,
panels a & b). The presence of chondrocytes and chondroid matrix
was evident in both groups with Alcian Blue staining (Fig. 6C,
panels c & d). Oil Red-O staining revealed that adipocytes and
preadipocytes were abundantly found in both groups (Fig. 6C,
panels e & f). Thus, the in vivo results strongly suggest that iMEFs
may give rise to osteogenic, chondrogenic and adipogenic lineages.
Furthermore, the immortalization of iMEFs can be reversed by
Cre recombinase, which may lead to a lower proliferative activity
and higher differentiation potential.
iMEFs are not tumorigenic in athymic nude mice
One of the major concerns over using immortalized progenitor
cells is their tumorigenic potential. Although SV40 large T antigen
is not considered an oncogene in mammalian cells, it remains
unclear if the T antigen would transform MEF progenitors and
render tumorigenicity. Thus, we sought to determine if iMEFs
Figure 5. The proliferation properties of the iMEFs can be reversed by Cre. (A) Efficient transduction of iMEFs by adenoviral vectors.
Subconfluent iMEFs were infected with AdCre (a) or AdGFP (b) for 24 h. GFP signal was recorded under fluorescence microscopy. (c) Cre-mediated
efficient removal of SV40 T Ag detected by Western blotting. Subconfluent iMEFs were infected with AdCre or AdGFP for 36 h. Cells were lysed, and
cell lysate was subjected to Western blotting using anti-SV40 T Ag antibody. Anti-ß-actin Western blotting confirms equal loading of the samples. (B)
Cell proliferation by viable cell counting. AdCre or AdGFP-transduced iMEFs were counted at indicated time points as described in Figure 2D.( C)
Cell proliferation assessed by crystal violet staining. AdCre or AdGFP-transduced iMEFs were stained with crystal violet at indicated time points as
described in Figure 2A.( D) Effect on ALP activity in iMEFs by Cre. AdCre or AdGFP-transduced iMEFs were stained for ALP activity at indicated time
points. (E) The effect of Cre-mediated reversal on late stage differentiation of the iMEFs. Subconfluent iMEFs were infected with AdCre or AdGFP and
maintained for 14 days. Cells were processed with Alizarin Red S staining (a and b) and Oil Red-O staining (c and d), or immunostained against
osteogenic late markers osteopontin (e and f) and osteocalcin (g and h). See Methods.
doi:10.1371/journal.pone.0032428.g005
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luciferase, we injected the cells into the flanks of athymic nude
mice subcutaneously. We used human osteosarcoma line 143B as
a positive control line. Cell proliferation at the injection sites was
monitored by using a small animal whole body bioluminescence
Xenogen IVIS 200 imaging system (Fig. 6D). We found that
while initial signal was strong (Fig. 6D), the signal rapidly
decreased at week 2 and became barely detectable at week 4. The
signal was undetectable in the injected animals for up to 10 weeks
and did not detect any tumor-like mass growth (data not shown).
In contrast, the 143B cells grew rapidly and formed rather large
xenograft tumors at week 4 (Fig. 6D). Taken together, these
results have demonstrated that while iMEFs have an increased
proliferative activity, they retain multipotency and are non-
tumorigenic. It has been well-documented that SV40 T antigen-
transformed cells are in general not tumorigenic [58–61]. Thus,
these cells may be used as model systems for MSC biology and
differentiation studies.
Figure 6. The iMEFs can effectively induce ectopic bone formation, chondrogenesis, and adipogenesis upon BMP9 stimulation in
vivo; and yet the iMEFs are non-tumorigenic. (A) The iMEFs without the removal of SV40 T Ag form larger ectopic bone masses. Subconfluent
iMEFs were co-infected with BMP9, GFP and/or Cre for 16 h. Cells were collected and injected into the flanks of athymic mice subcutaneously. Bony
masses were retrieved from mice after 4 weeks. No masses were formed in the cells transduced with AdGFP or AdCre alone. (B) H & E staining. The
retrieved bony masses were fixed, decalcified, and subjected to H & E staining. (C) Trichrome, Alcian Blue, and Oil Red-O staining of the retrieved
samples. AC, adipocyte; CC, chondrocyte; CM, chondroid matrix; MOM, mineralized osteoid matrix; OM, osteoid matrix. (D) Potential tumorigenicity of
the iMEFs. The iMEFs and human osteosarcoma line 143B cells were stably labeled with firefly luciferase and injected into the flanks of athymic nude
mice (2610
6 cells/injection). At the indicated time points, animal were anesthetized with isoflurane and injected (i.p.) with D-Luciferin sodium salt at
100 mg/kg in 0.1 ml sterile saline. Bioluminescence imaging was conducted with the Xenogen IVIS 200 imaging system. The pseudoimages were
obtained by superimposing the emitted light over the gray-scale photographs of the animals. Representative results are shown.
doi:10.1371/journal.pone.0032428.g006
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Primary MEFs serve as a rich source of mesenchymal
progenitor cells, and have become a popular source of MSCs.
Primary MEFs are also widely used as the feeder layer for
culturing embryonic stem cells [62]. It is believed that MEFs can
provide factors that enhance the proliferation and maintain the
undifferentiated states of embryonic stem cells. Because the life
span of primary MEFs is limited and isolation of primary MEFs is
time-consuming and labor-intensive, there is always an essential
need to develop MEFs with permanent growth features. Two
major approaches have been developed to immortalize primary
MEFs, including the serial passages of primary MEFs until they
overcome their growth-crisis stage and the transformation of
primary MEFs by overexpression of one or more oncogenes. The
serial passage has been used to establish the BALB/3T3 cell line
[63]. However, most of these established MEF lines were
hypotetraploid [63]. Furthermore, it is unclear if these transformed
cells retain multi-lineage differentiation potential. Numerous
studies have been recently carried out to induce the pluripotency
of fibroblasts and MEFs through reprogramming stem cell
differentiation capability with a set of defined factors, such as
Oct3/4, Sox9, Klf4, and c-Myc [54–57].
We investigate whether immortalized MEFs retain the multip-
otent properties of mesenchymal stem cells (MSCs) by taking
advantage of a previously characterized reversible immortalization
system using SV40 T antigen [28]. The reversible immortalization
vector SSR #69 contains the hygromycin and SV40 T antigen
expression cassette flanked with Cre/loxP sites [28]. Our results
show that MEFs can be effectively immortalized with SV40 T
antigen, and the proliferative activity of the iMEFs can be
effectively reversed by Cre recombinase. The immortalized MEFs
(iMEFs) express most of the MSC markers. Growth and
differentiation factor BMP9 up-regulates the key lineage-specific
regulators Runx2 (osteogenic), Sox9 (chondrogenic) and PPARc2
(adipogenic), and induces osteogenic marker ALP activity and
matrix mineralization in the iMEFs in vitro. The iMEFs are able to
undergo terminal adipogenic differentiation upon BMP9 or
PPARc2 stimulation. Furthermore, in vivo stem cell implantation
studies indicate that the iMEFs are able to bone, cartilage and
adipose tissues upon BMP9 stimulation, whereas in the presence of
Cre recombinase the ability of iMEFs to differentiate into these
tissues is decreased largely due to the reduced expansion of
progenitor population. Taken together, our results have demon-
strated that the reversibly immortalized iMEFs not only maintain
long-term cell proliferation but also retain the ability to
differentiate into multiple lineages. The reversible SV40 T-
mediated immortalization strategy should be used to establish
stable cells from primary progenitors isolated from limited tissue
sources, which would be critical for basic and translational studies.
The large T antigen encoded by simian virus 40 (SV40) plays
essential roles in the infection of permissive cells, leading to
production of progeny virions, and in the infection of nonpermis-
sive cells, leading to malignant transformation [64,65]. Primary
MEFs are nonpermissive for SV40, and infection by wild-type
SV40 leads to immortalization and transformation of a small
percentage of infected cells. The ability of SV40 large T antigen to
immortalize MEFs is largely dependent on its ability to complex
with p53 [66]. Thus, SV40 T antigen has become one of the most
commonly used gene to immortalize primary mammalian cells. In
this report, we demonstrate that the iMEFs are not tumorigenic at
least within the duration of observation. The Cre-mediated
reversal of the immortalization phenotypes should further enhance
the safety profile of this strategy. Nonetheless, it is noteworthy that
the Cre-mediated excision of SV40 T antigen is not footprintless as
a significant portion of the retroviral vector, such as LTRs and
packaging signal, remains integrated in the host genome.
Traditional cell immortalization and transformation strategies
have been widely used in cancer research [67]. Those transfor-
mation approaches usually involves in overexpression of onco-
genes and/or inactivation of tumor suppressor genes. Many other
genes have been used to immortalize primary cells. The commonly
used oncogenes may include k-ras, c-myc, CDK4, cyclin D1, Bmi-
1, and HPV 16 E6/E7, to name a few, while the frequently
inactivated tumor suppressor gens are p53, Rb, and p16
INK, etc.
Unlike these oncogenes, it has been well-documented that SV40 T
antigen-transformed cells are in general not tumorigenic [58–61].
Another commonly used gene for immortalization is telomerase
(TERT) [68]. The telomerase complex maintains telomere length,
which is required for an unlimited cellular proliferation.
Telomerase is low or absent in normal human somatic cells.
Telomerase expression is high in stem cells but reduced upon
differentiation. Restoring telomerase activity in normal somatic
cells can indefinitely prolong cellular life span, which may be
associated with the acquisition of characteristics typical of cellular
transformation [69]. Ectopic expression of the catalytic subunit of
mouse telomerase (mTERT) confers a growth advantage to
primary MEFsand facilitates their spontaneous immortalization by
targeting the TGFb pathway [70]. A recent study indicated that
ectopic expression of mouse telomerase catalytic subunit
(mTERT) does not affect embryonic stem (ES) cell proliferation
or differentiation in vitro, but protects ES cells against cell death
during differentiation [71]. Nonetheless, the efficiency and
differentiation potential of TERT-immortalized MSCs need to
thoroughly investigated.
In summary, to overcome the challenges in maintaining
sufficient MSCs for in vitro and in vivo studies, as well as for
possible clinical applications, we demonstrate that MEFs can be
efficiently immortalized by SV40 T antigen. The reversibly
immortalized iMEFs exhibit high proliferative activity and
maintain long-term cell proliferation, which can be reversed by
introducing Cre recombinase. The immortalized MEFs express
most of the MSC markers and retain multipotent differentiation
potential as they can differentiate into osteogenic, chondrogenic
and adipogenic lineages under appropriate differentiating condi-
tions both in vitro and in vivo. Furthermore, the immortalized MEFs
are apparently not tumorigenic when subcutaneously injected into
athymic nude mice. Thus, the reversible SV40 T antigen-
mediated immortalization is an efficient and safe approach to
establishing long-term cell culture of primary mesenchymal
progenitors for basic and translational research. This reversible
immortalization strategy should be a valuable tool for studying
primary progenitors which are isolated from limited tissue
availability.
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